CYCN · As filed with the SEC
Korsana Biosciences cash flow statement, by quarter
The statement as Korsana Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Statements of Cash Flows (Unaudited) · USD
| USD | Q2 2026 3 months ended Jun 30, 2026 | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024† 3 months ended Dec 31, 2024 | Q3 2024 3 months ended Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | — | (3,177,000) | — | — | — | (1,429,000) | — | — |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Share-based compensation expense | — | 58,000 | — | — | — | 114,000 | — | — |
| Gain on disposal of discontinued operations | — | — | — | — | — | — | 0† | — |
| Impairment loss | — | — | — | — | — | — | 0† | — |
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | — | 1,000,000 | — | — | — | (25,000) | — | — |
| Prepaid expenses | — | 129,000 | — | — | — | 165,000 | — | — |
| Other current assets | — | 0 | — | — | — | (5,000) | — | — |
| Accounts payable | — | (51,000) | — | — | — | 93,000 | — | — |
| Accrued research and development costs | — | (50,000) | — | — | — | (2,000) | — | — |
| Accrued expenses and other current liabilities | — | 915,000 | — | — | — | 121,000 | — | — |
| Net cash used in operating activities | — | (1,176,000) | — | — | — | (968,000) | — | — |
| Net proceeds from disposal of discontinued operations | — | — | — | — | — | — | 0† | — |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Purchases of property and equipment | — | (66,000) | — | — | — | — | — | — |
| Net cash used in investing activities | — | (66,000) | — | — | — | — | — | — |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from ATM | — | 825,000 | — | — | — | — | — | — |
| Proceeds from private placement | — | — | — | — | — | 1,375,000 | — | — |
| Net cash provided by financing activities | — | 825,000 | — | — | — | 1,375,000 | — | — |
| Effect of exchange rate changes on cash and cash equivalents | — | — | — | — | — | 0 | — | — |
| Net decrease in cash and cash equivalents | — | (417,000) | — | — | — | 407,000 | — | — |
| Cash and cash equivalents, beginning of period | 2,823,000 | 3,240,000 | 4,568,000 | 3,006,000 | 3,639,000 | 3,232,000 | 2,872,000 | 4,588,000 |
| Cash and cash equivalents, end of period | 1,391,000 | 2,823,000 | 3,240,000 | 4,568,000 | 3,006,000 | 3,639,000 | 3,232,000 | 2,872,000 |
| Issuance cost included in the accrued expense and other current liabilities | — | — | — | — | — | 130,000 | — | — |
| Non-cash gain on disposal of discontinued operations | — | — | — | — | — | — | 0† | — |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.